drugset

drugset / Trial / NCT01798238

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

NCT01798238 ↗

Phase 3 Completed 142 enrolled Handok Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The study design of this trial is double blind, parallel-group, randomized, placebo controlled study

Timeline

Start: 2012-11
Primary completion: 2014-05
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Teneligliptin	Small molecule	20 mg	Oral

Indications